Johnson & Johnson subsidiary Biologics Delivery Systems Group, Cordis of Miami Lakes, FL, said it will appeal yesterday's decision by a U.S. District Court judge upholding a jury finding last year in Wilmington, DE, in favor of interventional device firm Boston Scientific of Natick, MA, on stent patents.
The ruling found Boston Scientific's Ding patent to be valid and infringed by Cordis' Cypher sirolimus-eluting stent. The Ding patent claims a two-layer drug coating on a drug-eluting stent.
In a related decision, the judge also upheld the portion of a July 2005 jury verdict that found Boston Scientific's Jang patent to be valid and infringed, under the doctrine of equivalents, by Cordis' Cypher sirolimus-eluting coronary stent and Bx Velocity family of stent products. The Jang patent claims specific stent geometry.
Cordis said it will appeal the judge's decisions on the Jang patent and the Ding patent to the Court of Appeals for the Federal Circuit in Washington, DC.
By AuntMinnie.com staff writers
June 16, 2006
Related Reading
Boston Scientific wins J&J patent appeal, June 16, 2006
Cordis unveils next-generation transhepatic biliary stent, June 9, 2006
Cordis to establish Silicon Valley research center, May 25, 2006
Cordis releases Smart stent, May 16, 2006
Boston Scientific, J&J get mixed ruling on stent disputes, May 12, 2006
Copyright © 2006 AuntMinnie.com
